NASDAQ
Fate Therapeutics, Inc. (FATE)
♥ 606 Thanks from members
Fate Therapeutics demonstrates financial stabilization with $153.8M liquidity and promising clinical progress in its off-the-shelf iPSC-derived CAR T-cell pipeline, specifically FT819 for autoimmune diseases like lupus nephritis, though near-term index headwinds and clinical enrollment bottlenecks temper broader market sentiment.